Dergiler / Clinical and Experimental Ocular Trauma and Infection / 2019 / Cilt: 1 - Sayı: 1

Intravitreal Injection Endophthalmitis Results: Two Different Rooms

Sayfa
32–36
Yayın Tarihi
2019-04-23
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Conclusion: We found no difference between performing IVIs in a theatre versus in a dedicated room.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Purpose: To compare postoperative complication rates of intravitreal injections (IVIs) when performed in dedicated rooms versus performed in standard surgical rooms.
📊
Temel Bulgular & Veri:Material and methods: Group 1 underwent IVIs in the operating room, Group 2 underwent IVIs in a dedicated room with high-efficiency particulate air filtering device (PFD) on mode (0.02 %).
💡
Sonuç & Katkı:Conclusion: We found no difference between performing IVIs in a theatre versus in a dedicated room.
🔬Tür:Literatür & Derleme Çalışması
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:hospital productivity · endophthalmitis · dedicated room

Abstract

Purpose: To compare postoperative complication rates of intravitreal injections (IVIs) when performed in dedicated rooms versus performed in standard surgical rooms. Material and methods: Group 1 underwent IVIs in the operating room, Group 2 underwent IVIs in a dedicated room with high-efficiency particulate air filtering device (PFD) on mode (0.02 %). Postoperative complications, room particle counts were evaluated. Results: A total of 13354 injections consisting of 652 females (48 %) and 680 males (52 %) who had undergone intravitreal injection were reviewed. Endophthalmitis was observed in a total of 3 injections (0,022%), 2 patients in the operating room (0.02%), and 1 patient in the dedicated room. Conclusion: We found no difference between performing IVIs in a theatre versus in a dedicated room.

🔖

Bu Makaleye Atıf Yap

ÇEVİK, S. G., ÇEVİK, M. T., AKDOĞAN, M. (2019). Intravitreal Injection Endophthalmitis Results: Two Different Rooms. Clinical and Experimental Ocular Trauma and Infection, Cilt: 1 - Sayı: 1, 32–36. https://ajindex.com/articles/827425

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (14)

  1. Jager RD, Aiello LP, Patel SC,et al. Risks of intravitreous injection: a comprehensive review. Retina. 2004;24:676698
  2. Pilli S, Kotsolis A, Spaide RF, et al. Endophthalmitis associated with intravitreal anti-vascular endothelial growth factor therapy injections in an office setting. Am J Ophthalmol. 2008;145:879-882
  3. Abell RG, Kerr NM, Allen P, et al. Intravitreal injections: is there benefit for a theatre setting? Br J Ophthalmol. 2012;96:14741478
  4. Van der Reis MI, La Heij EC, De Jong-Hesse Y, et al. A systematic review of the adverse events of intravitreal anti-vascular endothelial growth factor injections. Retina 2011;31:1449–1469
  5. Elman MJ, Ayala A, Bressler NM, et al. Diabetic Retinopathy Clinical Research Network. Intravitreal Ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: 5-year randomized trial results. Ophthalmology. 2015;122:375-381
  6. Sun Y, Qu Y. Comparison of intravitreal bevacizumab with intravitreal triamcinolone acetonide for the treatment of cystoid macular edema secondary to retinal vein occlusion: a Meta-analysis. Int J Ophthalmol. 2015;8(6):1234-1239
  7. Gillies MC, Lim LL, Campain A, et al. A randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for diabetic macular edema: the BEVORDEX study. Ophthalmology. 2014;121:2473-2481
  8. Arevalo JF, Jap A, Chee SP, et al. Endogenous endophthalmitis in the developing world. Int Ophthalmol Clin. 2010;50:173-187
  9. Dharan S, Pittet D. Environmental controls in operating theatres. J Hosp Infect. 2002;51:79-84
  10. Lapid-Gortzak R, Traversari R, van der Linden JW, et al. Mobile ultra-clean unidirectional airflow screen reduces air contamination in a simulated setting for intravitreal injection. Int Ophthalmol. 2017; 37(1):131-137
  11. The Royal College of Ophthalmologists, United Kingdom. The UK Guidelines for Intravitreal Injections Procedure 2009
  12. Bande MF, Mansilla R, Pata MP, et al. Intravitreal injections of anti-VEGF agents and antibiotic prophylaxis for endophthalmitis: A systematic review and meta-analysis. Sci Rep. 2017;7:18088
  13. Tabandeh H, Boscia F, Sborgia A, et al. Endophthalmitis associated with intravitreal injections: office-based setting and operating room setting. Retina. 2014;;34:1823
  14. McCannel CA. Meta-analysis of endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents: causative organisms and possible prevention strategies. Retina 2011;31:6